1313363-54-0

NVP-CGM097 is a potent and selective MDM2 inhibitor with IC50 of 1.7±0.1 nM for hMDM2.

NVP-CGM097 is a potent and selective MDM2 inhibitor with a Ki value of 1.3 nM. It binds to the p53-binding site of the MDM2 protein, disrupting its protein-protein interactions, leading to activation of the p53 pathway.

The binding ability of NVP-CGM097 to MDM2 varies among different species. The selectivity of it for p53:MDM2 interaction is 1176-fold for p53:MDM4 interaction, 3000-fold for Ras:Raf interaction, and 1176-fold for Bcl-2:Bak, Bcl-2:Bad, Mcl- The interaction of 1:Bak, Mcl-1:NOXA, XIAP:BIR3, c-IAP:BIR3 is inactive, therefore, it is highly selective for p53:MDM2. It can significantly promote the entry of wild-type p53 into the nucleus with IC50 of 0.224 μM, indicating that it can inhibit the p53:MDM2 interaction in living cells. It promotes p53 as nucleus, resulting in cellular p53-dependent growth inhibition.

After intravenous injection, the serum clearance of NVP-CGM097 was 5 mL/min/kg in mice, 7 mL/min/kg in rats, 3 mL/min/kg in dogs, and 3 mL/min/kg in monkeys. 4 mL/min/kg. Serum clearance of NVP-CGM097 was low in all species compared to hepatic blood flow (typically 5-10% hepatic blood flow). The half-life of NVP-CGM097 in rodents and monkeys is 6-12 hours; in dogs, the half-life is 20 hours, which is relatively longer.

Target	Value
hMDM2 (Cell-free assay)	1.7 nM

Store at -20°C

[1] Holzer P, et al. Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem. 2015 Aug 27;58(16):6348-58 DOI:10.1021/acs.jmedchem.5b00810